

## Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following statements is true regarding the Phase III ALCYONE trial of bortezomib/melphalan/prednisone with or without daratumumab for patients with multiple myeloma (MM)?
  - Patients had newly diagnosed MM
  - Patients had received high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
  - Patients were younger than 65
- Results from the Phase I/II study of ixazomib, lenalidomide and dexamethasone followed by ixazomib maintenance therapy for patients with newly diagnosed MM demonstrated that \_\_\_\_\_.
  - The rate of very good partial response or better was lower for patients who did not receive stem cell transplantation than for the overall study population
  - Maintenance ixazomib led to an improved response for 32% of patients
  - Of the patients who achieved complete response or stringent complete response, 11% achieved minimal residual disease (MRD)-negative status
  - All of the above
- Updated analysis from the Phase III CALGB (Alliance) 100104 study comparing lenalidomide to placebo as maintenance therapy following single ASCT failed to demonstrate a significant difference in \_\_\_\_\_.
  - Progression-free survival (PFS)
  - Overall survival
  - Overall survival after disease progression
- A presentation at ASH 2017 by De Tute and colleagues analyzing the Myeloma XI trial suggested that patients who converted from MRD-negative status after ASCT to MRD-positive after 6 months of maintenance therapy had a statistically \_\_\_\_\_ progression-free survival in comparison to those whose status remained MRD-positive throughout.
  - Higher
  - Lower
  - Similar
- More than 75% of patients with symptomatic MM on the Phase Ib EQUULEUS study of daratumumab with pomalidomide and dexamethasone experienced Grade 3 or 4 \_\_\_\_\_.
  - Infusion-related reactions
  - Pneumonia
  - Neutropenia
- The Phase III ENDEAVOR study comparing carfilzomib with dexamethasone to bortezomib with dexamethasone for patients with relapsed/refractory MM demonstrated a significant improvement in PFS with carfilzomib.
  - True
  - False
- Early studies of chimeric antigen receptor T-cell therapy for relapsed/refractory MM have used receptors targeting \_\_\_\_\_, an antigen frequently expressed on MM cells.
  - CD19
  - BCMA
  - Bcl-2

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. According to data from the Phase III study comparing denosumab to zoledronic acid for newly diagnosed MM, patients treated with denosumab \_\_\_\_\_.

- a. Have a lower incidence of hypocalcemia
- b. Have a significantly higher median time to first on-study skeletal-related event
- c. Have a lower incidence of renal toxicity

9. A retrospective analysis by Kaufman and colleagues of daratumumab in patients with previously treated amyloid light-chain amyloidosis suggests that a majority of these patients who receive daratumumab \_\_\_\_\_.

- a. Experience cardiac toxicity
- b. Experience myelotoxicity
- c. Achieve a hematologic response

10. A presentation by Gustine and colleagues of an analysis of patients with Waldenström macroglobulinemia treated with ibrutinib demonstrated that of patients who discontinued ibrutinib treatment, fewer than 25% experienced IgM rebound.

- a. True
- b. False